- Home
- DMAC vs WEYS Comparison
DMAC vs WEYS Comparison
Compare DMAC & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- WEYS
- Stock Information
- Founded
- DMAC 2000
- WEYS 1906
- Country
- DMAC United States
- WEYS United States
- Employees
- DMAC N/A
- WEYS N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- WEYS Apparel
- Sector
- DMAC Health Care
- WEYS Consumer Staples
- Exchange
- DMAC Nasdaq
- WEYS Nasdaq
- Market Cap
- DMAC 310.1M
- WEYS 294.5M
- IPO Year
- DMAC N/A
- WEYS N/A
- Fundamental
- Price
- DMAC $6.96
- WEYS $28.92
- Analyst Decision
- DMAC Strong Buy
- WEYS
- Analyst Count
- DMAC 3
- WEYS 0
- Target Price
- DMAC $12.33
- WEYS N/A
- AVG Volume (30 Days)
- DMAC 343.5K
- WEYS 14.3K
- Earning Date
- DMAC 11-12-2025
- WEYS 11-04-2025
- Dividend Yield
- DMAC N/A
- WEYS 3.73%
- EPS Growth
- DMAC N/A
- WEYS N/A
- EPS
- DMAC N/A
- WEYS 2.69
- Revenue
- DMAC N/A
- WEYS $281,051,000.00
- Revenue This Year
- DMAC N/A
- WEYS N/A
- Revenue Next Year
- DMAC N/A
- WEYS N/A
- P/E Ratio
- DMAC N/A
- WEYS $10.65
- Revenue Growth
- DMAC N/A
- WEYS N/A
- 52 Week Low
- DMAC $3.19
- WEYS $25.51
- 52 Week High
- DMAC $7.49
- WEYS $41.05
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- WEYS 38.70
- Support Level
- DMAC $6.75
- WEYS $29.61
- Resistance Level
- DMAC $7.13
- WEYS $30.41
- Average True Range (ATR)
- DMAC 0.28
- WEYS 0.80
- MACD
- DMAC -0.06
- WEYS -0.11
- Stochastic Oscillator
- DMAC 50.00
- WEYS 0.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About WEYS Weyco Group Inc.
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.